A Novel Nanocomposite Drug Delivery System for SARS-CoV-2 Infections

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2024 Jul 25

PMID 39050946

Authors

Uday Chintapula

Shazeed-Ul Karim

Priyanka Raghunathan Iyer

Haritha Asokan-Sheeja

Biswas Neupane

Farzana Nazneen

He Dong

Fengwei Bai

Kytai T Nguyen

Affiliations

Soon will be listed here.

Abstract

To develop an inhalable drug delivery system, we synthesized poly (lactic--glycolic acid) nanoparticles with Remdesivir (RDV NPs) as an antiviral agent against SARS-CoV-2 replication and formulated Remdesivir-loaded nanocomposites (RDV NCs) coating of RDV NPs with novel supramolecular cell-penetrating peptide nanofibers (NFs) to enhance cellular uptake and intracellular drug delivery. RDV NPs and RDV NCs were characterized using variou techniques, including Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), and fluorescent microscopy. The cytotoxicity of RDV NCs was assessed in Vero E6 cells and primary human lung epithelial cells, with no significant cytotoxicity observed up to 1000 μg mL and 48 h. RDV NCs were spherically shaped with a size range of 200-300 nm and a zeta potential of ∼+31 mV as well as indicating the presence of coated nanofibers. Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR), immunofluorescence and plaque assays of SARS-CoV-2 infected Vero E6 treated with RDV NCs showed significantly higher antiviral activities compared to those of free drug and uncoated RDV NPs. RDV NCs exhibited high antiviral activity against SARS-CoV-2, and the nanocomposite platform has the potential to be developed into an inhalable drug delivery system for other viral infections in the lungs.

Citing Articles

Recent Advances in Antiviral Drug Delivery Strategies.

Rana D, Prajapati A, Karunakaran B, Vora L, Benival D, Jindal A AAPS PharmSciTech. 2025; 26(3):73.

PMID: 40038154 DOI: 10.1208/s12249-025-03053-3.

References

Mendoza E, Manguiat K, Wood H, Drebot M . Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol. 2020; 57(1):ecpmc105. PMC: 7300432. DOI: 10.1002/cpmc.105. View

Sadeghian I, Heidari R, Sadeghian S, Javad Raee M, Negahdaripour M . Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines. Eur J Pharm Sci. 2021; 169:106094. DOI: 10.1016/j.ejps.2021.106094. View

Jurek S, Hirano-Kobayashi M, Chiang H, Kohane D, Matthews B . Prevention of ventilator-induced lung edema by inhalation of nanoparticles releasing ruthenium red. Am J Respir Cell Mol Biol. 2014; 50(6):1107-17. PMC: 4068911. DOI: 10.1165/rcmb.2013-0163OC. View

Mandal S, Prathipati P, Belshan M, Destache C . A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study. Antiviral Res. 2019; 167:83-88. PMC: 7263829. DOI: 10.1016/j.antiviral.2019.04.007. View

Emam M, Nageh H, Ali F, Taha M, ElShehaby H, Amin R . Inhibition of SARS-CoV-2 spike protein entry using biologically modified polyacrylonitrile nanofibers: study towards specific antiviral masks. RSC Adv. 2022; 12(25):16184-16193. PMC: 9155179. DOI: 10.1039/d2ra01321e. View

Faust J, Kumar A, Shah J, Khadke S, Dani S, Ganatra S . Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023; 77(9):1257-1264. DOI: 10.1093/cid/ciad400. View

Abo-Zeid Y, Williams G, Touabi L, McLean G . An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles. Int J Pharm. 2020; 589:119826. PMC: 7836899. DOI: 10.1016/j.ijpharm.2020.119826. View

Chintapula U, Yang S, Nguyen T, Li Y, Jaworski J, Dong H . Supramolecular Peptide Nanofiber/PLGA Nanocomposites for Enhancing Pulmonary Drug Delivery. ACS Appl Mater Interfaces. 2022; 14(51):56498-56509. DOI: 10.1021/acsami.2c15204. View

Derakhshankhah H, Jafari S . Cell penetrating peptides: A concise review with emphasis on biomedical applications. Biomed Pharmacother. 2018; 108:1090-1096. DOI: 10.1016/j.biopha.2018.09.097. View

10.

Yang H, Li J, Patel S, Palmer K, Devlin B, Rohan L . Design of Poly(lactic--glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis. Pharmaceutics. 2019; 11(4). PMC: 6523646. DOI: 10.3390/pharmaceutics11040184. View

11.

Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly S . Nanotechnology based therapeutics for lung disease. Thorax. 2019; 74(10):965-976. DOI: 10.1136/thoraxjnl-2019-213037. View

12.

Sadat Mousavi Maleki M, Sardari S, Ghandehari Alavijeh A, Madanchi H . Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals. Int J Pept Res Ther. 2022; 29(1):5. PMC: 9702942. DOI: 10.1007/s10989-022-10477-z. View

13.

Hulme K, Gallo L, Short K . Influenza Virus and Glycemic Variability in Diabetes: A Killer Combination?. Front Microbiol. 2017; 8:861. PMC: 5438975. DOI: 10.3389/fmicb.2017.00861. View

14.

Essaidi-Laziosi M, Perez Rodriguez F, Hulo N, Jacquerioz F, Kaiser L, Eckerle I . Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells. Lancet Microbe. 2021; 2(11):e571. PMC: 8397300. DOI: 10.1016/S2666-5247(21)00216-0. View

15.

Cai X, Chen M, Prominski A, Lin Y, Ankenbruck N, Rosenberg J . A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Adv Sci (Weinh). 2021; 9(2):e2103240. PMC: 8646742. DOI: 10.1002/advs.202103240. View

16.

Bai F, Wang T, Pal U, Bao F, Gould L, Fikrig E . Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis. 2005; 191(7):1148-54. DOI: 10.1086/428507. View

17.

Bai F, Kong K, Dai J, Qian F, Zhang L, Brown C . A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J Infect Dis. 2010; 202(12):1804-12. PMC: 3053000. DOI: 10.1086/657416. View

18.

Sun M, Lai H, Huang J, Liu J, Li Y, Tian J . Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients. J Antimicrob Chemother. 2023; 78(9):2131-2139. DOI: 10.1093/jac/dkad216. View

19.

Gandhi S, Klein J, Robertson A, Pena-Hernandez M, Lin M, Roychoudhury P . De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022; 13(1):1547. PMC: 8930970. DOI: 10.1038/s41467-022-29104-y. View

20.

DAlmeida A, Pacheco de Oliveira M, de Souza E, Coutinho D, Ciambarella B, Gomes C . α-bisabolol-loaded lipid-core nanocapsules reduce lipopolysaccharide-induced pulmonary inflammation in mice. Int J Nanomedicine. 2017; 12:4479-4491. PMC: 5484570. DOI: 10.2147/IJN.S130798. View